Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.60, reflecting a +1.8% change from the previous day's closing price, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, the company's shares have appreciated by 10.29%, contrasting with the Medical sector's decline of 3.4% and the S&P 500's increase of 4.51% [1] Upcoming Financial Results - Ginkgo Bioworks is expected to report earnings of -$1.44 per share, indicating a year-over-year growth of 55%, while revenue is projected to be $43 million, representing a 23.5% decline compared to the same quarter last year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Ginkgo Bioworks are crucial as they indicate shifting business trends, with positive revisions suggesting analyst optimism about profitability [3] - The Zacks Rank system, which evaluates these estimate changes, currently assigns Ginkgo Bioworks a rank of 2 (Buy), indicating a favorable outlook [5] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]